PARKINSON DISEASE

New SPECT agent for detecting Parkinson's disease

New SPECT agent for detecting Parkinson's disease

Introduction

The purpose of this study is to expand the boundaries of the author's knowledge by exploring some relevant facts related to detection of Parkinson's disease through New SPECT agent. In this paper the author will examine the suitability of New SPECT agent for detecting Parkinson's disease.

Background of the research

Parkinson disease is a neurological disorder that directly affects the functioning of brain. According to a survey, approximately 0.3% people are suffering from this disorder. It is a progressive and chronic disorder; chances of occurrences are more in people age over 65 years. Male and female both have similar exposition to this problem; however it has been observed that men are more exposed to get affected by this disorder condition. Chances of its occurrence increase greatly with the increase in age of a person. Prevalence of Parkinson disease is higher in North American and European countries. Contrastingly, Asians and Black Africans are least exposed to this mental illness condition. China, Japan, Taiwan, and Australia are classified as least affected countries from PD.

It is mainly caused when dopamine-producing cells undergo idiopathic degeneration in the substantia nigra, a component in central brain. It is caused by numerous factors external to the state of a person, having more negative impact on person's mental state as he grow older. Different studies have examined the risk of Parkinson Disease occurrence as impact of environmental exposures.

Cogwheel rigidity, tremor, and bradykinesia are cardinal signs of this problem. It is difficult to diagnose this problem timely due to absence in proper reference diagnosis test. Pharmacological, surgical, psychiatric, and ancillary treatment are the common modes of treatment. It is mainly diagnosed clinically, but only 25% people have recovered from this problem partially or completely. L-dopa doses are the foundation of pharmacological treatment, including 'dopamine agonists' which is also used in some instances in combination with L-dopa for the treatment of Parkinson Disease. These tests directly affect dopamine receptors and increase dopamine levels through catabolism activity. Although a number of treatment methods are available, but nearly all PD patients are given L-dopa medication to assuage its symptoms while maintaining proper functioning of brain.

Problem Statement

“The role New SPECT agent for detecting Parkinson's disease”

Research Questions

What are the results of neuroimaging studies (CT, MRI, PET, and New SPECT) or other diagnostic tests in determining the diagnosis of PD?

What are the results of L-dopa challenge in PD? What is the accuracy, sensitivity and specificity of this test for diagnosing PD?

What serious adverse events are associated with medications used to treat PD?

Aims and Objective of the research

Main objective of this study is to determine the suitability of New SPECT agent for curing the problem if it is diagnosed in early stages or at advanced stages. Following that, another objective is to test relation between time of evaluation and its impact on change-score effect sizes. In last, this research will try exploring the problems/biological complications that are associated with the use of medication for treating ...